MedPath

Peri-operative chemotherapy with intraperitoneal and intravenous Paclitaxel plus TS-1 for serosa positive gastric cancer patients

Not Applicable
Conditions
serosa positive gastric cancer
Registration Number
JPRN-UMIN000013109
Lead Sponsor
Intraperitoneal chemotherapy study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

(i)The occurrence of simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor that is curable with local therapy (ii)A history of severe drug hypersensitivity (iii)The presence of active bacterial or fungal infection, and a body temperature over 38 temperature. (iv)Pregnancy or lactation in women of childbearing potential (v)Men who wish the partners pregnancy (vi)The presence of unstable angina, heart failure or a history of myocardial infarction within 6 months (vii)Patients requiring systemic steroid medication (viii)Patients requiring the administration of phenytoin or warfarin potassium (ix)The presence to peptic ulcer or bleeding (x)The presence of severe diarrhea (xi)The presence of antigen-positive serum HBs and/or antibody positive serum HVC (xii)The presence of uncontrollable intestinal paralysis, interstitial pneumonitis or ischemic heart disease (xiii)Patients determined to be inappropriate for this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
percent completion of protocol treatment
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath